Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
Morgan H. James, Jennifer E. Fragale, R. Nisha Aurora, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 5, pp. 717-719
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
Sex Differences in Demand for Highly Palatable Foods: Role of the Orexin System
Linnea R. Freeman, Brandon S. Bentzley, Morgan H. James, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 54-63
Open Access | Times Cited: 59
Sleep dysregulation in binge eating disorder and “food addiction”: the orexin (hypocretin) system as a potential neurobiological link
Jacqueline B. Mehr, Deborah Mitchison, Hannah E. Bowrey, et al.
Neuropsychopharmacology (2021) Vol. 46, Iss. 12, pp. 2051-2061
Open Access | Times Cited: 46
Orexin Reserve: A Mechanistic Framework for the Role of Orexins (Hypocretins) in Addiction
Morgan H. James, Gary Aston‐Jones
Biological Psychiatry (2022) Vol. 92, Iss. 11, pp. 836-844
Open Access | Times Cited: 33
IUPHAR Review: New strategies for medications to treat substance use disorders
Iván D. Montoya, Nora D. Volkow
Pharmacological Research (2024) Vol. 200, pp. 107078-107078
Open Access | Times Cited: 7
Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.
Andrew S. Huhn, Patrick H. Finan
Experimental and Clinical Psychopharmacology (2021) Vol. 30, Iss. 6, pp. 1024-1035
Open Access | Times Cited: 38
Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value
Alessandra Matzeu, Rémi Martin‐Fardon
Frontiers in Behavioral Neuroscience (2022) Vol. 15
Open Access | Times Cited: 26
Sleep loss and addiction
Luis Angel López-Muciño, Fabio Garcı́a-Garcı́a, Jonathan Cueto‐Escobedo, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 141, pp. 104832-104832
Closed Access | Times Cited: 26
Sleep Loss and Substance Use Disorders: An Issue from Adolescents to Adults
Ana Clementina Equihua-Benítez, Rodolfo Espinoza-Abad, Fabio Garcı́a-Garcı́a
Behavioral Sciences (2025) Vol. 15, Iss. 2, pp. 220-220
Open Access
The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System
Jennifer E. Fragale, Morgan H. James, Jorge A. Avila, et al.
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 117-127
Open Access | Times Cited: 29
Endogenous opiates and behavior: 2020
Richard J. Bodnar
Peptides (2022) Vol. 151, pp. 170752-170752
Closed Access | Times Cited: 19
The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
Margaret Moline, Shoji Asakura, Carsten Beuckman, et al.
Psychopharmacology (2023) Vol. 240, Iss. 4, pp. 699-711
Open Access | Times Cited: 11
The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse
Morgan H. James, Jennifer E. Fragale, Shayna L. O’Connor, et al.
Neuropharmacology (2020) Vol. 183, pp. 108359-108359
Open Access | Times Cited: 29
Age-specific treatment effects of orexin/hypocretin-receptor antagonism on methamphetamine-seeking behavior
Natalie E. Zlebnik, Nathan A. Holtz, Victoria C. Lepak, et al.
Drug and Alcohol Dependence (2021) Vol. 224, pp. 108719-108719
Open Access | Times Cited: 24
New directions in modelling dysregulated reward seeking for food and drugs
Robyn M. Brown, Christopher V. Dayas, Morgan H. James, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 1037-1048
Open Access | Times Cited: 23
Oxytocin and orexin systems bidirectionally regulate the ability of opioid cues to bias reward seeking
Giuseppe Giannotti, Francesca Mottarlini, Jasper A. Heinsbroek, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 17
Contribution of hypothalamic orexin (hypocretin) circuits to pathologies of motivation
Aida Mohammadkhani, Caitlin Mitchell, Morgan H. James, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 3
At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities
Mark K. Greenwald, Tabitha E.H. Moses, Timothy Roehrs
Translational research (2021) Vol. 234, pp. 58-73
Open Access | Times Cited: 20
Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses
Santosh Kumar Prajapati, Sairam Krishnamurthy
Behavioural Brain Research (2020) Vol. 399, pp. 113015-113015
Closed Access | Times Cited: 23
Targeting the Orexin System for Prescription Opioid Use Disorder
Alessandra Matzeu, Rémi Martin‐Fardon
Brain Sciences (2020) Vol. 10, Iss. 4, pp. 226-226
Open Access | Times Cited: 22
Introduction to the Special Issue: “Making orexin-based therapies for addiction a reality: What are the steps from here?”
Morgan H. James, Gary Aston‐Jones
Brain Research (2020) Vol. 1731, pp. 146665-146665
Open Access | Times Cited: 21
Suvorexant enhances oxycodone-induced respiratory depression in male rats
Eliseu da Cruz Moreira-Junior, James K. Rowlett, Laís F. Berro
Drug and Alcohol Dependence (2024) Vol. 264, pp. 112434-112434
Closed Access | Times Cited: 2
Sleep-mediated regulation of reward circuits: implications in substance use disorders
Rong Guo, Dylan T. Vaughan, Ana L. Almeida Rojo, et al.
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 61-78
Open Access | Times Cited: 12
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder
Brian D. Kiluk, Bethea A. Kleykamp, Sandra D. Comer, et al.
JAMA Psychiatry (2022) Vol. 80, Iss. 1, pp. 84-84
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top